Gloriana Therapeutics, Inc.
https://glorianatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gloriana Therapeutics, Inc.
Novo Nordisk Bets $256m On Mystery Molecule
The Danish group has licensed an unnamed product with an unknown mechanism.
Evotec Adds To Spate Of Metabolic Deals With Lilly Collaboration
The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Lilly to develop kidney disease and diabetes assets.
Another R&D Deal For Takeda As It Inks Parkinson’s Alliance
Deals and R&D partnerships are coming thick and fast for Takeda in the first few days of the year, with the major Japanese firm unveiling a new tie-up with NsGene to progress direct-delivered cell therapies for Parkinson's disease.
Biogen Idec buys analgesic developer Convergence for $200m+
Biogen Idec has agreed to pay $200m up front and up to $475m in milestones to acquire the UK developer of drugs for neuropathic pain Convergence Pharmaceuticals. The target company's most promising pipeline drug is CNV1014802, which has yielded positive Phase II results for trigeminal neuralgia (TGN), an orphan condition characterized by excruciating face pain.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Medical Devices
- Consumables, Central Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Laser
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- NsGene A/S
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice